CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
? Q4 2025 Net Revenue of $128.6 million ? ? Pro Forma Full Year 2025 Net Revenue of $401.3 million ? ? Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ? ? Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ? PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed $91.2 million of net revenue in the quarter.For the full-year 2025, CorMedix achieved total revenue of $311.7 million and pro forma total revenue of $401.3 million.
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026GlobeNewswire
- Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline? [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. (CRMD) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/6/26 - Form 4
- CRMD's page on the SEC website